BioSpace5d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she says she experienced when taking opioids.
RBC says Journavx review documents hint at focus in future chronic pain data
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
FiercePharma29d
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex Pharmaceuticals has scored an FDA approval for Journavx (suzetrigine), a non-opioid pain reliever that could usher in a new era of nonaddictive therapy in the indication. As an oral voltage ...
Newsweek29d
What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades
Vertex Pharmaceuticals Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences ...
Business Insider29d
Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
Journavx reduces pain by targeting a pain ... Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on VRTX: Vertex Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies ...
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
USA Today28d
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a listen-only mode. [Operator instructions] Please note, this event is being ...
The Washington Post26d
FDA approves new, non-opioid painkiller Journavx
Vertex Pharmaceuticals, which makes the drug, has billed it as an effective alternative to opioids that isn’t addictive. Journavx works by intercepting pain signals before they reach the spinal ...